Descubra el nuevo Chem-Impex: donde la innovación comienza con un vínculo.

Catalog Number:
32472
CAS Number:
78287-27-1
7-Etilcamptotecina
Purity:
≥ 99 % (HPLC)
Synonym(s):
(4 S )-4,11-Dietil-4-hidroxi-1 H -pirano[3',4':6,7]indolizino[1,2-b]quinolina-3,14(4 H ,12 H )-diona
Hazmat
Documents
$51.18 /250 mg
Tamaño
Request Bulk Quote
Información del producto

Mantener el envase bien cerrado en un lugar seco y bien ventilado.

Número CAS
78287-27-1
Fórmula molecular
C22H20N2O4
Peso molecular
0
Número MDL
MFCD06657922
Punto de fusión
258 - 260 °C (descenso)
Rotación óptica
[a]20/D= 40 a 46° (C=0,4 en CHCl3:MeOH=8:2)
Condiciones
Tienda en RT
Información general
Número CAS
78287-27-1
Fórmula molecular
C22H20N2O4
Peso molecular
0
Número MDL
MFCD06657922
Punto de fusión
258 - 260 °C (descenso)
Rotación óptica
[a]20/D= 40 a 46° (C=0,4 en CHCl3:MeOH=8:2)
Condiciones
Tienda en RT
Propiedades
¡Pronto habrá más información sobre la propiedad!
-
Seguridad y normativas
Materiales peligrosos
-
Antibiótico
-
Regulado por la DEA
No
Advertencias
-
Aplicaciones

7-Ethylcamptothecin is widely utilized in research focused on:

  • Cancer Treatment: This compound is a potent inhibitor of topoisomerase I, making it a valuable candidate in the development of anti-cancer therapies. It has shown promising results in clinical trials for various cancers, including colorectal and lung cancer.
  • Pharmaceutical Development: Researchers are exploring its potential in formulating new drugs that can overcome resistance seen with traditional chemotherapy agents. Its unique structure allows for modifications that can enhance efficacy and reduce side effects.
  • Drug Delivery Systems: Due to its hydrophobic nature, 7-Ethylcamptothecin can be incorporated into nanocarriers for targeted drug delivery, improving the concentration of the drug at tumor sites while minimizing systemic exposure.
  • Research on Mechanisms of Action: Scientists use this compound to study the mechanisms of DNA damage and repair, providing insights into cellular responses to chemotherapy and helping to identify biomarkers for treatment efficacy.
  • Combination Therapies: It is being investigated in combination with other therapeutic agents to enhance overall treatment outcomes, particularly in resistant cancer types, showcasing its versatility in oncology.

Citas